Increased serum CXCL10 in Graves’ disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process | Zendy

Alessandro Antonelli | Zendy; Poupak Fallahi | Zendy; Mario Rotondi | Zendy; Silvia Martina Ferrari | Zendy; Paola Romagnani | Zendy; M Grosso | Zendy; Ele Ferrannini | Zendy; Mario Serio | Zendy

Open Access

Increased serum CXCL10 in Graves’ disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process

Author(s) -

Alessandro Antonelli,

Poupak Fallahi,

Mario Rotondi,

Silvia Martina Ferrari,

Paola Romagnani,

M Grosso,

Ele Ferrannini,

Mario Serio

Publication year - 2006

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.1.02137

Subject(s) - medicine , levothyroxine , endocrinology , autoimmune thyroiditis , thyroiditis , autoimmune disease , graves' disease , thyroid , thyroid cancer , disease

Serum CXCL10 (an interferon-gamma-inducible chemokine) levels (sCXCL10) are increased in several autoimmune conditions, including Graves' disease (GD) and autoimmune thyroiditis (AT). Longitudinal assessment of sCXCL10 in autoimmune hypo- or hyperthyroidism has not yet been performed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research